RT Journal Article
SR Electronic
T1 Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3741
OP 3746
VO 36
IS 7
A1 YOICHIRO YOSHIDA
A1 MASAYASU NAITO
A1 TEPPEI YAMADA
A1 NAOYA AISU
A1 KOJIMA DAIBO
A1 TOSHIYUKI MERA
A1 TOSHIHIRO TANAKA
A1 KEIKO NAITO
A1 KOSEI YASUMOTO
A1 TAKASHI KAMIGAKI
A1 SHIGENORI GOTO
A1 YUICHI YAMASHITA
A1 SUGURU HASEGAWA
YR 2016
UL http://ar.iiarjournals.org/content/36/7/3741.abstract
AB Background/Aim: Adoptive immunotherapy of cancer is evolving with the development of novel technologies that generate proliferation of large numbers of αβ and γδ T cells. We evaluated the safety and efficacy of the combination of adoptive immunotherapy using αβ T cells with chemotherapy for stage IV colorectal cancer (CRC). Patients and Methods: Fifteen patients with advanced or recurrent CRC received XELOX + bevacizumab + ex vivo expanded αβ T lymphocytes as a first-line chemoimmunotherapy. Results: Median age of the 15 patients (4 men, 11 women) was 65 years (range=49-80). Median progression-free survival was 21.3 months. Response rate was 80% (complete response (CR)=26.7%, partial response (PR)=53.3%, stable disease (SD)=20% and progressive disease (PD)=0%). Most adverse events were mild to moderate regarding their intensity and immunotherapy-associated toxicity was minimal. Conclusion: Combination of adoptive αβ T cell immunotherapy with chemotherapy for stage IV CRC is feasible and safe.